Human dengue virus serotype 2 neutralizing antibodies target two distinct quaternary epitopes

PLoS Pathogens
Emily GallichotteAravinda M de Silva

Abstract

Dengue virus (DENV) infection causes dengue fever, dengue hemorrhagic fever and dengue shock syndrome. It is estimated that a third of the world's population is at risk for infection, with an estimated 390 million infections annually. Dengue virus serotype 2 (DENV2) causes severe epidemics, and the leading tetravalent dengue vaccine has lower efficacy against DENV2 compared to the other 3 serotypes. In natural DENV2 infections, strongly neutralizing type-specific antibodies provide protection against subsequent DENV2 infection. While the epitopes of some human DENV2 type-specific antibodies have been mapped, it is not known if these are representative of the polyclonal antibody response. Using structure-guided immunogen design and reverse genetics, we generated a panel of recombinant viruses containing amino acid alterations and epitope transplants between different serotypes. Using this panel of recombinant viruses in binding, competition, and neutralization assays, we have finely mapped the epitopes of three human DENV2 type-specific monoclonal antibodies, finding shared and distinct epitope regions. Additionally, we used these recombinant viruses and polyclonal sera to dissect the epitope-specific responses following primary...Continue Reading

References

Dec 31, 2003·Advances in Virus Research·John T Roehrig
Feb 6, 2009·Emerging Infectious Diseases·Nalaka KanakaratneMaya Gunasekera
Apr 4, 2009·The Journal of Immunology : Official Journal of the American Association of Immunologists·Lauren E YauchSujan Shresta
May 23, 2009·Infection, Genetics and Evolution : Journal of Molecular Epidemiology and Evolutionary Genetics in Infectious Diseases·Scott C Weaver, Nikos Vasilakis
Feb 23, 2012·Viruses·Wahala M P B Wahala, Aravinda M de Silva
Apr 14, 2012·Proceedings of the National Academy of Sciences of the United States of America·Ruklanthi de AlwisAravinda M de Silva
Apr 9, 2013·Nature·Samir BhattSimon I Hay
Apr 13, 2013·Proceedings of the National Academy of Sciences of the United States of America·Daniela WeiskopfAlessandro Sette
Nov 5, 2014·The New England Journal of Medicine·Luis VillarUNKNOWN CYD15 Study Group
Jan 17, 2015·Nature Immunology·Josefina Coloma, Eva Harris
May 20, 2015·Vaccine·Lauren M SchwartzIra M Longini
Nov 26, 2015·Nature Reviews. Immunology·Gavin ScreatonCatherine Roberts
Dec 8, 2015·Nature Reviews. Microbiology·Bruno Guy, Nicholas Jackson
Jan 6, 2016·Proceedings of the National Academy of Sciences of the United States of America·Leah C KatzelnickEva Harris
Feb 6, 2016·PLoS Neglected Tropical Diseases·Brett M ForsheySteven T Stoddard
Mar 5, 2016·Protein Science : a Publication of the Protein Society·Nicolas ChéronEugene I Shakhnovich
Oct 18, 2016·EBioMedicine·Annie Elong NgonoSujan Shresta
Jun 20, 2017·Journal of Clinical Neuroscience : Official Journal of the Neurosurgical Society of Australasia·Wan Aliaa Wan SulaimanHamidon Basri
Jul 5, 2017·Scientific Reports·Stefan W MetzAravinda M de Silva
Oct 31, 2017·Frontiers in Immunology·Alba GrifoniDaniela Weiskopf
Nov 4, 2017·Science·Leah C KatzelnickEva Harris

❮ Previous
Next ❯

Citations

Jul 25, 2019·Current Drug Targets·M Elizabeth SobhiaSunilchand Donempudi
Jul 3, 2020·Journal of Virology·Ashlie ThomasStefan W Metz

❮ Previous
Next ❯

Methods Mentioned

BETA
ELISA

Related Concepts

Related Feeds

Aminoglycosides (ASM)

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.

Aminoglycosides

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.

Antibody Specificity

Antibodies produced by B cells are highly specific for antigen as a result of random gene recombination and somatic hypermutation and affinity maturation. As the main effector of the humoral immune system, antibodies can neutralize foreign cells. Find the latest research on antibody specificity here.